Patents by Inventor Bernd Michael Loeffler

Bernd Michael Loeffler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190151354
    Abstract: The use of gaseous oxygen for the production of a therapeutic gas for inhalation by a patient who has been identified as a person with a mitochondrial disorder or a coenzyme Q10 deficiency, for the treatment of mitochondrial disorders or Q10 deficiencies is disclosed. For the first time a non-invasive method is disclosed, upon what the body's own level of Q10 can be raised significantly without further interventions.
    Type: Application
    Filed: September 19, 2018
    Publication date: May 23, 2019
    Inventor: Bernd-Michael Loeffler
  • Patent number: 10117893
    Abstract: The use of gaseous oxygen for the production of a therapeutic gas for inhalation by a patient who has been identified as a person with a mitochondrial disorder or a coenzyme Q10 deficiency, for the treatment of mitochondrial disorders or Q10 deficiencies is disclosed. For the first time a non-invasive method is disclosed, upon what the body's own level of Q10 can be raised significantly without further interventions.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: November 6, 2018
    Inventor: Bernd-Michael Loeffler
  • Publication number: 20120213863
    Abstract: The use of gaseous oxygen for the production of a therapeutic gas for inhalation by a patient who has been identified as a person with a mitochondrial disorder or a coenzyme Q10 deficiency, for the treatment of mitochondrial disorders or Q10 deficiencies is disclosed. For the first time a non-invasive method is disclosed, upon what the body's own level of Q10 can be raised significantly without further interventions.
    Type: Application
    Filed: October 27, 2010
    Publication date: August 23, 2012
    Applicant: CELLGYM TECHNOLOGIES GMBH
    Inventor: Bernd-Michael Loeffler
  • Publication number: 20120045509
    Abstract: The present invention refers to pharmaceutical composition comprising a DPP-IV inhibitor.
    Type: Application
    Filed: October 27, 2011
    Publication date: February 23, 2012
    Inventors: Bernd Michael Loeffler, Alexander MacDonald, Cynthia Rocha, Eric Worth
  • Patent number: 7803819
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.
    Type: Grant
    Filed: July 17, 2007
    Date of Patent: September 28, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Markus Boehringer, Daniel Hunziker, Holger Kuehne, Bernd Michael Loeffler, Ramakanth Sarabu, Hans Peter Wessel
  • Publication number: 20100222340
    Abstract: The present invention relates to compounds of formula (I) wherein R1 to R4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.
    Type: Application
    Filed: May 13, 2010
    Publication date: September 2, 2010
    Inventors: Markus Boehringer, Daniel Hunziker, Bernd Kuhn, Bernd Michael Loeffler, Fabienne Ricklin, Hans Peter Wessel
  • Publication number: 20100087485
    Abstract: The present invention relates to compounds of the formula (I) wherein R1 and R2 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, non-insulin dependent diabetes mellitus and/or impaired glucose tolerance, obesity, and/or metabolic syndrome or ?-cell protection.
    Type: Application
    Filed: December 9, 2009
    Publication date: April 8, 2010
    Inventors: Markus Boehringer, Daniel Hunziker, Bernd Kuhn, Bernd Michael Loeffler, Thomas Luebbers, Fabienne Ricklin
  • Patent number: 7683079
    Abstract: The present invention relates to compounds of the formula (I) wherein R1 and R2 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, non-insulin dependent diabetes mellitus and/or impaired glucose tolerance, obesity, and/or metabolic syndrome or ?-cell protection.
    Type: Grant
    Filed: December 14, 2005
    Date of Patent: March 23, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Markus Boehringer, Daniel Hunziker, Bernd Kuhn, Bernd Michael Loeffler, Thomas Luebbers, Fabienne Ricklin
  • Patent number: 7411093
    Abstract: The present invention relates to compounds of formula (I) wherein R1 is as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.
    Type: Grant
    Filed: December 13, 2005
    Date of Patent: August 12, 2008
    Assignee: Hoffman-La Roche Inc.
    Inventors: Markus Boehringer, Daniel Hunziker, Bernd Kuhn, Bernd Michael Loeffler, Hans Peter Marty, Patrizio Mattei, Robert Narquizian
  • Patent number: 7314884
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.
    Type: Grant
    Filed: December 13, 2004
    Date of Patent: January 1, 2008
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Markus Boehringer, Daniel Hunziker, Holger Kuehne, Bernd Michael Loeffler, Ramakanth Sarabu, Hans Peter Wessel
  • Patent number: 7022718
    Abstract: The present invention provides compounds of formula (I) wherein R1, R2, R3, R4 and X are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.
    Type: Grant
    Filed: January 18, 2005
    Date of Patent: April 4, 2006
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Markus Boehringer, Bernd Michael Loeffler, Jens-Uwe Peters, Matthias Steger, Peter Weiss
  • Patent number: 6867205
    Abstract: The present invention provides compounds of formula (I) wherein R1, R2, R3, R4 and X are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.
    Type: Grant
    Filed: February 10, 2003
    Date of Patent: March 15, 2005
    Assignee: Hoffman-La Roche Inc.
    Inventors: Markus Boehringer, Bernd Michael Loeffler, Jens-Uwe Peters, Matthias Steger, Peter Weiss
  • Patent number: 6861440
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.
    Type: Grant
    Filed: October 14, 2002
    Date of Patent: March 1, 2005
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Markus Boehringer, Daniel Hunziker, Holger Kuehne, Bernd Michael Loeffler, Ramakanth Sarabu, Hans Peter Wessel
  • Patent number: 6800650
    Abstract: The present invention provides compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.
    Type: Grant
    Filed: February 11, 2003
    Date of Patent: October 5, 2004
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Markus Boehringer, Bernd Michael Loeffler, Jens-Uwe Peters, Claus Riemer, Peter Weiss
  • Publication number: 20030216382
    Abstract: The present invention provides compounds of formula (I) 1
    Type: Application
    Filed: February 10, 2003
    Publication date: November 20, 2003
    Inventors: Markus Boehringer, Bernd Michael Loeffler, Jens-Uwe Peters, Matthias Steger, Peter Weiss
  • Publication number: 20030195188
    Abstract: The present invention provides compounds of formula (I) 1
    Type: Application
    Filed: February 11, 2003
    Publication date: October 16, 2003
    Inventors: Markus Boehringer, Bernd Michael Loeffler, Jens-Uwe Peters, Claus Riemer, Peter Weiss
  • Patent number: 6541638
    Abstract: The present invention relates to pyrrolidine derivatives and dimeric forms and/or pharmaceutically acceptable esters, and/or salts thereof. The compounds are useful as inhibitors of metalloproteases, e.g. zinc proteases, particularly zinc hydrolases, and which are effective in treating disease states are associated with vasoconstriction of increasing occurrences.
    Type: Grant
    Filed: July 17, 2001
    Date of Patent: April 1, 2003
    Assignee: Hoffman-La Roche Inc.
    Inventors: Johannes Aebi, Denise Blum, Daniel Bur, Alexander Chucholowski, Henrietta Dehmlow, Eric Argirios Kitas, Bernd Michael Loeffler, Ulrike Obst, Sabine Wallbaum
  • Publication number: 20020049243
    Abstract: The present invention relates to pyrrolidine derivatives and dimeric forms and/or pharmaceutically acceptable esters, and/or salts thereof. The compounds are useful as inhibitors of metalloproteases, e.g. zinc proteases, particularly zinc hydrolases, and which are effective in treating disease states are associated with vasoconstriction of increasing occurrences.
    Type: Application
    Filed: July 17, 2001
    Publication date: April 25, 2002
    Inventors: Johannes Aebi, Denise Blum, Daniel Bur, Alexander Chucholowski, Henrietta Dehmlow, Eric Argirios Kitas, Bernd Michael Loeffler, Ulrike Obst, Sabine Wallbaum